Get the Stockscreener App
17.17
1.66%
-0.29
Pre-market:
17.17
Omeros Corp stock is traded at $17.17, with a volume of 1.66M.
It is down -1.66% in the last 24 hours and down -0.12% over the past month.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
See More
Previous Close:
$17.46
Open:
$17.26
24h Volume:
1.66M
Relative Volume:
0.83
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
$84.01M
P/E Ratio:
20.06
EPS:
0.856
Net Cash Flow:
$-101.16M
1W Performance:
-10.20%
1M Performance:
-0.12%
6M Performance:
+53.44%
1Y Performance:
+319.80%
1-Day Range:
$16.50
$17.40
1-Week Range:
$16.50
$19.55
52-Week Range:
$3.94
$19.65
Omeros Corp Stock (OMER) Company Profile
Name
Omeros Corp
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
17.17 | 1.32B | 0 | 84.01M | -101.16M | 0.856 |
VRTX
Vertex Pharmaceuticals Inc
|
514.63 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.11 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
979.76 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.77 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
204.86 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corp Stock (OMER) Latest News
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
Omeros Stock Price Forecast. Should You Buy OMER? - StockInvest.us
Omeros Corp VP and General Counsel Peter B. Cancelmo Executes Stock Option Exercises and Sells Shares - Kalkine Media
Omeros Insider Sold Shares Worth $929,668, According to a Recent SEC Filing - marketscreener.com
Omeros VP, finance & CAO David Borges sells $206,804 in shares By Investing.com - Investing.com South Africa
Omeros VP, finance & CAO David Borges sells $206,804 in shares - Investing.com Nigeria
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Omeros VP of finance David Borges sells $206,804 in shares By Investing.com - Investing.com Nigeria
Omeros VP of finance David Borges sells $206,804 in shares - investing.com
Omeros Corp (OMER) Director Thomas Cable Sells 15,000 Shares - GuruFocus
Omeros director Thomas Cable sells $276,772 in company stock - Investing.com
Omeros director Thomas Cable sells $276,772 in company stock By Investing.com - Investing.com Canada
Omeros (NASDAQ:OMER) Director Thomas Cable Sells 15,000 Shares - MarketBeat
Omeros (NASDAQ: OMER) officer to sell 10,906 shares - Stock Titan
Omeros Corp (OMER) director lines up fresh stock sale - Stock Titan
Pomerantz investigates Omeros after CHMP negative opinion - scanx.trade
Omeros (NASDAQ:OMER) Sets New 52-Week HighStill a Buy? - MarketBeat
Omeros stock hits 52-week high at 18.16 USD - Investing.com
Omeros stock hits 52-week high at 18.16 USD By Investing.com - Investing.com Canada
Omeros Corp (OMER) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Omeros Corp (HAM:3O8) Stock Price, Trades & News - GuruFocus
Omeros VP, finance & CAO Borges sells $84,750 in shares - Investing.com India
Omeros VP, finance & CAO Borges sells $84,750 in shares By Investing.com - Investing.com South Africa
Omeros (NASDAQ:OMER) CAO David Borges Sells 5,000 Shares of Stock - MarketBeat
HC Wainwright Comments on Omeros' Q3 Earnings (NASDAQ:OMER) - MarketBeat
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
Teleconferência de Resultados do 2T26 da Omeros (OMER): Vendas do YARTEMLEA Atingem US$ 28,5 Milhões - TradingKey
Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Buy - MarketBeat
Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Omeros (OMER) Turns Profitable As Investors Ask If The Repricing Has Gone Too Far - Yahoo Finance
Omeros Corporation Releases Q2 2026 Earnings Call Summary as Pipeline Development Remains in Focus - Vinanet
What is HC Wainwright's Forecast for Omeros FY2029 Earnings? - MarketBeat
Omeros Corporation $OMER Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
OMER SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
OMEROS CORP SEC Filing (Aug 13, 2026) - Stock Titan
Omeros Corporation Announces Appointment of Joseph Schocken as Director and Audit Committee Member, Effective August 12, 2026 - marketscreener.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Biotech Stocks To ConsiderAugust 13th - MarketBeat
Omeros Sees Unusually Large Options Volume (NASDAQ:OMER) - MarketBeat
Omeros (NASDAQ:OMER) Sets New 52-Week High Following Better-Than-Expected Earnings - MarketBeat
Omeros Corp (OMER) Shares Surge 29% on Q2 Beat; Price-to-Sales V - GuruFocus
Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday - Benzinga
Why is Omeros stock surging today? By Investing.com - Investing.com South Africa
Why is Omeros stock surging today? - Investing.com
Omeros Corp (OMER) Shares Surge 15% on Q2 Boost; Price-to-Sales Valuation Raises Growth Expectations - GuruFocus
Why Omeros Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Omeros Q2 2026 Earnings Call Transcript - MarketBeat
Portnoy Law Firm investigates Omeros after CHMP negative opinion - scanx.trade
Omeros Corp (OMER) Posts $28.5M Net Sales for YARTEMLEA's Debut Quarter Amid Valuation Concerns - GuruFocus
Omeros Corp Swings To Q2 Profit On YARTEMLEA Momentum; Plans ARDS, TA-TMA Studies; Shares Rise - RTTNews
Omeros Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Omeros Corp Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omeros Corp Stock (OMER) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cancelmo Peter B | VP, General Counsel |
Aug 31 '26 |
Option Exercise |
2.94 |
25,000 |
73,500 |
25,200 |
| Cancelmo Peter B | VP, General Counsel |
Aug 28 '26 |
Sale |
18.65 |
25,000 |
466,128 |
200 |
| Cancelmo Peter B | VP, General Counsel |
Aug 31 '26 |
Sale |
18.54 |
25,000 |
463,540 |
200 |
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):